Lennard J M Dekker
Overview
Explore the profile of Lennard J M Dekker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paauw A, Scholz H, Mars-Groenendijk R, Dekker L, Luider T, van Leeuwen H
PLoS Negl Trop Dis
. 2023 Jan;
17(1):e0011006.
PMID: 36607891
Background: Burkholderia mallei and Burkholderia pseudomallei are both potential biological threat agents. Melioidosis caused by B. pseudomallei is endemic in Southeast Asia and Northern Australia, while glanders caused by B....
2.
Hagenaars S, Dekker L, Ravesteijn B, van Vlierberghe R, Romijn F, Verhoeff L, et al.
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293255
The prospective, multicenter TESTBREAST study was initiated with the aim of identifying a novel panel of blood-based protein biomarkers to enable early breast cancer detection for moderate-to-high-risk women. Serum samples...
3.
Foudraine D, Dekker L, Strepis N, Nispeling S, Raaphorst M, Kloezen W, et al.
Front Microbiol
. 2022 Jul;
13:887420.
PMID: 35814653
New and rapid antimicrobial susceptibility/resistance testing methods are required for bacteria from positive blood cultures. In this study, a multiplex-targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed and validated...
4.
Foudraine D, Aarents C, Wattel A, van Boxtel R, Strepis N, Ten Kate M, et al.
Front Microbiol
. 2022 Mar;
13:793738.
PMID: 35295306
While Extended-Spectrum β-Lactamases (ESBL) and AmpC β-lactamases barely degrade carbapenem antibiotics, they are able to bind carbapenems and prevent them from interacting with penicillin-binding proteins, thereby inhibiting their activity. Further,...
5.
Dekker L, Verheul C, Wensveen N, Leenders W, Lamfers M, Leenstra S, et al.
ACS Omega
. 2022 Feb;
7(4):3568-3578.
PMID: 35128264
The R132H mutation in the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) is the most important prognostic factor for the survival of glioma patients. Subsequent studies led to the discovery of...
6.
Rosu M, Kok A, Bestebroer T, de Meulder D, Verveer E, Pronk M, et al.
J Virol
. 2022 Feb;
96(6):e0195921.
PMID: 35107371
Seasonal influenza vaccination takes into account primarily hemagglutinin (HA)-specific neutralizing antibody responses. However, the accumulation of substitutions in the antigenic regions of HA (i.e., antigenic drift) occasionally results in a...
7.
Foudraine D, Strepis N, Stingl C, Ten Kate M, Verbon A, Klaassen C, et al.
Sci Rep
. 2021 Jun;
11(1):12472.
PMID: 34127720
Antimicrobial resistance is mostly studied by means of phenotypic growth inhibition determinations, in combination with PCR confirmations or further characterization by means of whole genome sequencing (WGS). However, the actual...
8.
Foudraine D, Strepis N, Klaassen C, Raaphorst M, Verbon A, Luider T, et al.
J Clin Microbiol
. 2021 Apr;
59(7):e0046421.
PMID: 33910961
New and rapid diagnostic methods are needed for the detection of antimicrobial resistance to aid in curbing drug-resistant infections. Targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a method that could...
9.
Zeneyedpour L, Stingl C, Dekker L, Mustafa D, Kros J, Luider T
J Proteome Res
. 2020 Aug;
19(10):4179-4190.
PMID: 32811146
Formalin-fixed paraffin-embedded (FFPE) tissues are routinely prepared and collected for diagnostics in pathology departments. These are, therefore, the most accessible research sources in pathology archives. In this study we investigated...
10.
Dekker L, Kannegieter N, Haerkens F, Toth E, Kros J, Steenhoff Hov D, et al.
Neurooncol Adv
. 2020 Aug;
2(1):vdaa083.
PMID: 32793885
Background: Despite maximal therapy with surgery, chemotherapy, and radiotherapy, glioblastoma (GBM) patients have a median survival of only 15 months. Almost all patients inevitably experience symptomatic tumor recurrence. A hallmark...